Irritable Bowel Syndrome Treatment global market

Irritable Bowel Syndrome Treatment global market

Global Irritable Bowel Syndrome Treatment Market Research Report 2025

This report on the global irritable bowel syndrome treatment market research report 2025 offers a comprehensive analysis of market size, growth drivers, emerging tre

Pages: 210

Format: PDF

Date: 12-2025

Select Licence

Global Irritable Bowel Syndrome (IBS) Treatment Market Outlook (2025–2035)

Chem Reports predicts that the IBS Treatment Market, valued at USD xxxx million in 2024, is expected to reach USD xxxx million by 2035, growing at a CAGR of xx% globally.

Market Overview

The Global IBS Treatment Market Report 2020 provides an extensive industry analysis of development drivers, structural patterns, market flows, and size evolution. Historical and present market values have been assessed to forecast growth trajectories for the period 2025–2035.

This research integrates primary and secondary data sources, evaluating:

  • Government policies and regulatory frameworks
  • Market environment and competitive dynamics
  • Historical performance and current trends
  • Technological innovation and upcoming advancements
  • Cross-industry technical progress

Impact of COVID-19

The outbreak of COVID-19 in December 2019 disrupted global healthcare systems and pharmaceutical supply chains. Declared a public health emergency by the World Health Organization, the pandemic significantly impacted the IBS treatment market in 2020, with ripple effects across hospitals, clinics, and home care settings.

Market Segmentation

By Type

  • Lubiprostone
  • Linaclotide
  • Eluxadoline
  • Rifaximin
  • Ramosetron Hydrochloride
  • Others

By Application

  • Hospitals
  • Clinics
  • Home Care

Regional Analysis

  • North America: U.S., Canada, Mexico – Largest market, driven by advanced healthcare infrastructure, high prevalence of IBS, and strong adoption of novel therapies.
  • Europe: Germany, U.K., France, Italy, Russia, Spain – Adoption supported by innovation in gastrointestinal treatments and regulatory compliance.
  • Asia-Pacific: China, India, Japan, Southeast Asia – Fastest-growing region, driven by rising prevalence of IBS, expanding healthcare access, and government-backed initiatives.
  • South America: Brazil, Argentina – Moderate growth, supported by healthcare modernization and increasing awareness of gastrointestinal disorders.
  • Middle East & Africa: Saudi Arabia, South Africa – Emerging demand, particularly in hospitals and clinics addressing chronic gastrointestinal conditions.

Key Market Players

  • Abbott Laboratories
  • Synergy Pharmaceuticals Inc.
  • Sucampo Pharmaceuticals Inc.
  • Valeant Pharmaceuticals International Inc.
  • Ardelyx Inc.
  • Astellas Pharma Inc.
  • Novartis AG
  • GlaxoSmithKline plc.
  • Ironwood Pharmaceuticals Inc.

Strategic Insights

  • Growth Drivers: Rising prevalence of IBS worldwide, increasing demand for effective therapies, and innovation in gastrointestinal drug development.
  • Challenges: High treatment costs, regulatory hurdles, and limited patient awareness in developing regions.
  • Opportunities: Expansion in Asia-Pacific and Middle East, innovation in targeted therapies, and premium positioning in hospital and clinic-based treatments.

Regional Analysis

  • North America: Largest market, driven by advanced healthcare infrastructure, high prevalence of IBS, and strong adoption of novel therapies. The U.S. leads due to FDA approvals and high patient awareness.
  • Europe: Germany, U.K., France, and Italy emphasize innovation in gastrointestinal treatments and compliance with EMA regulations. Russia and Spain contribute through hospital-based adoption and clinical research.
  • Asia-Pacific: Fastest-growing region, led by China, India, and Japan. Rising prevalence of IBS, expanding healthcare access, and government-backed initiatives fuel demand. Southeast Asia is emerging as a hub for cost-effective treatment adoption.
  • South America: Brazil and Argentina show moderate growth, supported by healthcare modernization and increasing awareness of gastrointestinal disorders.
  • Middle East & Africa: Emerging demand, particularly in Saudi Arabia and South Africa, driven by hospital expansion and rising awareness of chronic gastrointestinal conditions.

Detailed Segmentation Analysis

  • By Type:
    • Lubiprostone: Widely used for IBS-C (constipation-predominant).
    • Linaclotide: Effective in IBS-C, with strong adoption in North America and Europe.
    • Eluxadoline: Applied in IBS-D (diarrhea-predominant).
    • Rifaximin: Antibiotic therapy for IBS-D, gaining traction in hospital settings.
    • Ramosetron Hydrochloride: Used in Asia-Pacific markets for IBS-D.
    • Others: Specialty drugs and pipeline therapies.
  • By Application:
  • Hospitals: Largest consumer segment, driven by advanced treatment adoption.
  • Clinics: Significant demand for outpatient IBS management.
  • Home Care: Emerging segment, supported by telemedicine and self-administered therapies.

Porter’s Five Forces

  • Threat of New Entrants: Moderate; barriers include regulatory approvals and clinical trial costs.
  • Supplier Power: Moderate; pharmaceutical suppliers hold leverage but competition balances pricing.
  • Buyer Power: High; hospitals and clinics demand cost-effective, high-performance therapies.
  • Threat of Substitutes: Moderate; alternatives include dietary management, probiotics, and lifestyle interventions.
  • Industry Rivalry: High; competition among established players (Abbott, Novartis, GSK, Ironwood, Astellas) and emerging biotech firms.

SWOT Analysis

Strengths: Essential therapies for IBS management; strong adoption in hospitals and clinics; established global providers.
Weaknesses: High treatment costs; limited patient awareness in developing regions.
Opportunities: Expansion in Asia-Pacific and Middle East; innovation in targeted therapies; premium positioning in hospital and clinic-based treatments.
Threats: Competition from alternative therapies; regulatory tightening; supply chain disruptions.

Trend Analysis

  • Rising demand for targeted therapies for IBS-C and IBS-D.
  • Growth in telemedicine and home care adoption.
  • Increasing adoption of antibiotic and peptide-based therapies.
  • Expansion into emerging markets with rising healthcare access.

Drivers & Challenges

Drivers:

  • Global demand for effective IBS management.
  • Rising prevalence of IBS worldwide.
  • Technological innovation in gastrointestinal drug development.

Challenges:

  • High treatment costs limiting adoption.
  • Regulatory hurdles in drug approvals.
  • Limited patient awareness in developing regions.

Value Chain Analysis

  • Raw Materials: Active pharmaceutical ingredients (APIs) for IBS therapies.
  • Manufacturing: Pharmaceutical companies producing IBS drugs.
  • Distribution: Hospitals, clinics, pharmacies, and telemedicine platforms.
  • End Users: IBS patients, healthcare providers, and caregivers.

Quick Recommendations for Stakeholders

  • Manufacturers: Invest in R&D for targeted IBS therapies; expand into Asia-Pacific and Middle East.
  • Investors: Focus on companies with diversified gastrointestinal portfolios and strong regulatory pipelines.
  • Healthcare Providers: Adopt advanced IBS therapies for outpatient and home care management.
  • Policy Makers: Support IBS awareness programs and incentivize drug innovation.

 

Explore more reports here-

https://chemreports.com/reports

 

 

1. Market Overview of Irritable Bowel Syndrome Treatment
    1.1 Irritable Bowel Syndrome Treatment Market Overview
        1.1.1 Irritable Bowel Syndrome Treatment Product Scope
        1.1.2 Market Status and Outlook
    1.2 Irritable Bowel Syndrome Treatment Market Size by Regions:
    1.3 Irritable Bowel Syndrome Treatment Historic Market Size by Regions
    1.4 Irritable Bowel Syndrome Treatment Forecasted Market Size by Regions
    1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
        1.5.1 North America
        1.5.2 East Asia
        1.5.3 Europe
        1.5.4 South Asia
        1.5.5 Southeast Asia
        1.5.6 Middle East
        1.5.7 Africa
        1.5.8 Oceania
        1.5.9 South America
        1.5.10 Rest of the World
    1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
        1.6.1 Covid-19 Impact: Global GDP Growth,  Projections
        1.6.2 Covid-19 Impact: Commodity Prices Indices
        1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Irritable Bowel Syndrome Treatment Sales Market by Type
    2.1 Global Irritable Bowel Syndrome Treatment Historic Market Size by Type
    2.2 Global Irritable Bowel Syndrome Treatment Forecasted Market Size by Type
    2.3 Lubiprostone
    2.4 Linaclotide
    2.5 Eluxadoline
    2.6 Rifaximin
    2.7 Ramosetron Hydrochloride
    2.8 Others
3. Covid-19 Impact Irritable Bowel Syndrome Treatment Sales Market by Application
    3.1 Global Irritable Bowel Syndrome Treatment Historic Market Size by Application
    3.2 Global Irritable Bowel Syndrome Treatment Forecasted Market Size by Application
    3.3 Hospital
    3.4 Clinic
    3.5 Home Care
4. Covid-19 Impact Market Competition by Manufacturers
    4.1 Global Irritable Bowel Syndrome Treatment Production Capacity Market Share by Manufacturers
    4.2 Global Irritable Bowel Syndrome Treatment Revenue Market Share by Manufacturers
    4.3 Global Irritable Bowel Syndrome Treatment Average Price by Manufacturers
5. Company Profiles and Key Figures in Irritable Bowel Syndrome Treatment Business
    5.1 Abbott Laboratories
        5.1.1 Abbott Laboratories Company Profile
        5.1.2 Abbott Laboratories Irritable Bowel Syndrome Treatment Product Specification
        5.1.3 Abbott Laboratories Irritable Bowel Syndrome Treatment Production Capacity, Revenue, Price and Gross Margin
    5.2 Synergy Pharmaceuticals Inc.
        5.2.1 Synergy Pharmaceuticals Inc. Company Profile
        5.2.2 Synergy Pharmaceuticals Inc. Irritable Bowel Syndrome Treatment Product Specification
        5.2.3 Synergy Pharmaceuticals Inc. Irritable Bowel Syndrome Treatment Production Capacity, Revenue, Price and Gross Margin
    5.3 Sucampo Pharmaceuticals Inc.
        5.3.1 Sucampo Pharmaceuticals Inc. Company Profile
        5.3.2 Sucampo Pharmaceuticals Inc. Irritable Bowel Syndrome Treatment Product Specification
        5.3.3 Sucampo Pharmaceuticals Inc. Irritable Bowel Syndrome Treatment Production Capacity, Revenue, Price and Gross Margin
    5.4 Valeant Pharmaceuticals International Inc.
        5.4.1 Valeant Pharmaceuticals International Inc. Company Profile
        5.4.2 Valeant Pharmaceuticals International Inc. Irritable Bowel Syndrome Treatment Product Specification
        5.4.3 Valeant Pharmaceuticals International Inc. Irritable Bowel Syndrome Treatment Production Capacity, Revenue, Price and Gross Margin
    5.5 Ardelyx Inc.
        5.5.1 Ardelyx Inc. Company Profile
        5.5.2 Ardelyx Inc. Irritable Bowel Syndrome Treatment Product Specification
        5.5.3 Ardelyx Inc. Irritable Bowel Syndrome Treatment Production Capacity, Revenue, Price and Gross Margin
    5.6 Astellas Pharma Inc.
        5.6.1 Astellas Pharma Inc. Company Profile
        5.6.2 Astellas Pharma Inc. Irritable Bowel Syndrome Treatment Product Specification
        5.6.3 Astellas Pharma Inc. Irritable Bowel Syndrome Treatment Production Capacity, Revenue, Price and Gross Margin
    5.7 Novartis AG
        5.7.1 Novartis AG Company Profile
        5.7.2 Novartis AG Irritable Bowel Syndrome Treatment Product Specification
        5.7.3 Novartis AG Irritable Bowel Syndrome Treatment Production Capacity, Revenue, Price and Gross Margin
    5.8 GlaxoSmithKline plc.
        5.8.1 GlaxoSmithKline plc. Company Profile
        5.8.2 GlaxoSmithKline plc. Irritable Bowel Syndrome Treatment Product Specification
        5.8.3 GlaxoSmithKline plc. Irritable Bowel Syndrome Treatment Production Capacity, Revenue, Price and Gross Margin
    5.9 Ironwood Pharmaceuticals Inc.
        5.9.1 Ironwood Pharmaceuticals Inc. Company Profile
        5.9.2 Ironwood Pharmaceuticals Inc. Irritable Bowel Syndrome Treatment Product Specification
        5.9.3 Ironwood Pharmaceuticals Inc. Irritable Bowel Syndrome Treatment Production Capacity, Revenue, Price and Gross Margin
6. North America
    6.1 North America Irritable Bowel Syndrome Treatment Market Size
    6.2 North America Irritable Bowel Syndrome Treatment Key Players in North America
    6.3 North America Irritable Bowel Syndrome Treatment Market Size by Type
    6.4 North America Irritable Bowel Syndrome Treatment Market Size by Application
7. East Asia
    7.1 East Asia Irritable Bowel Syndrome Treatment Market Size
    7.2 East Asia Irritable Bowel Syndrome Treatment Key Players in North America
    7.3 East Asia Irritable Bowel Syndrome Treatment Market Size by Type
    7.4 East Asia Irritable Bowel Syndrome Treatment Market Size by Application
8. Europe
    8.1 Europe Irritable Bowel Syndrome Treatment Market Size
    8.2 Europe Irritable Bowel Syndrome Treatment Key Players in North America
    8.3 Europe Irritable Bowel Syndrome Treatment Market Size by Type
    8.4 Europe Irritable Bowel Syndrome Treatment Market Size by Application
9. South Asia
    9.1 South Asia Irritable Bowel Syndrome Treatment Market Size
    9.2 South Asia Irritable Bowel Syndrome Treatment Key Players in North America
    9.3 South Asia Irritable Bowel Syndrome Treatment Market Size by Type
    9.4 South Asia Irritable Bowel Syndrome Treatment Market Size by Application
10. Southeast Asia
    10.1 Southeast Asia Irritable Bowel Syndrome Treatment Market Size
    10.2 Southeast Asia Irritable Bowel Syndrome Treatment Key Players in North America
    10.3 Southeast Asia Irritable Bowel Syndrome Treatment Market Size by Type
    10.4 Southeast Asia Irritable Bowel Syndrome Treatment Market Size by Application
11. Middle East
    11.1 Middle East Irritable Bowel Syndrome Treatment Market Size
    11.2 Middle East Irritable Bowel Syndrome Treatment Key Players in North America
    11.3 Middle East Irritable Bowel Syndrome Treatment Market Size by Type
    11.4 Middle East Irritable Bowel Syndrome Treatment Market Size by Application
12. Africa
    12.1 Africa Irritable Bowel Syndrome Treatment Market Size
    12.2 Africa Irritable Bowel Syndrome Treatment Key Players in North America
    12.3 Africa Irritable Bowel Syndrome Treatment Market Size by Type
    12.4 Africa Irritable Bowel Syndrome Treatment Market Size by Application
13. Oceania
    13.1 Oceania Irritable Bowel Syndrome Treatment Market Size
    13.2 Oceania Irritable Bowel Syndrome Treatment Key Players in North America
    13.3 Oceania Irritable Bowel Syndrome Treatment Market Size by Type
    13.4 Oceania Irritable Bowel Syndrome Treatment Market Size by Application
14. South America
    14.1 South America Irritable Bowel Syndrome Treatment Market Size
    14.2 South America Irritable Bowel Syndrome Treatment Key Players in North America
    14.3 South America Irritable Bowel Syndrome Treatment Market Size by Type
    14.4 South America Irritable Bowel Syndrome Treatment Market Size by Application
15. Rest of the World
    15.1 Rest of the World Irritable Bowel Syndrome Treatment Market Size
    15.2 Rest of the World Irritable Bowel Syndrome Treatment Key Players in North America
    15.3 Rest of the World Irritable Bowel Syndrome Treatment Market Size by Type
    15.4 Rest of the World Irritable Bowel Syndrome Treatment Market Size by Application
16 Irritable Bowel Syndrome Treatment Market Dynamics
    16.1 Covid-19 Impact Market Top Trends
    16.2 Covid-19 Impact Market Drivers
    16.3 Covid-19 Impact Market Challenges
    16.4 Porter?s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
    18.1 Research Methodology
        18.1.1 Methodology/Research Approach
        18.1.2 Data Source
    18.2 Disclaimer

Market Segmentation

By Type

  • Lubiprostone
  • Linaclotide
  • Eluxadoline
  • Rifaximin
  • Ramosetron Hydrochloride
  • Others

By Application

  • Hospitals
  • Clinics
  • Home Care

Regional Analysis

  • North America: U.S., Canada, Mexico – Largest market, driven by advanced healthcare infrastructure, high prevalence of IBS, and strong adoption of novel therapies.
  • Europe: Germany, U.K., France, Italy, Russia, Spain – Adoption supported by innovation in gastrointestinal treatments and regulatory compliance.
  • Asia-Pacific: China, India, Japan, Southeast Asia – Fastest-growing region, driven by rising prevalence of IBS, expanding healthcare access, and government-backed initiatives.
  • South America: Brazil, Argentina – Moderate growth, supported by healthcare modernization and increasing awareness of gastrointestinal disorders.
  • Middle East & Africa: Saudi Arabia, South Africa – Emerging demand, particularly in hospitals and clinics addressing chronic gastrointestinal conditions.

Key Market Players

  • Abbott Laboratories
  • Synergy Pharmaceuticals Inc.
  • Sucampo Pharmaceuticals Inc.
  • Valeant Pharmaceuticals International Inc.
  • Ardelyx Inc.
  • Astellas Pharma Inc.
  • Novartis AG
  • GlaxoSmithKline plc.
  • Ironwood Pharmaceuticals Inc.

Upto 24 to 48 hrs (Working Hours)

Upto 72 hrs max (Working Hours) - Weekends and Public Holidays

Single User License - Allows access to only one person to the report.

Multi User License - Allows sharing with max 5 persons within organization.

Corporate License – Can be shared across entire organization.

Online Payments with PayPal

Wire Transfer / Bank Transfer

Why Choose Us

24/7 Expert Support

At ChemReports, we understand that business decisions can’t wait. Our research specialists are available anytime to answer your queries and guide you through our reports, ensuring quick and reliable assistance.


Comprehensive Market Coverage

ChemReports provides 360° market analysis across materials, technologies, and global chemical sectors—helping you make confident business decisions.


Actionable Intelligence

We turn complex data into strategic insights to support fact-based decisions, market entry strategies, and competitive analysis.


Data Privacy & Security

Your personal and business information is completely secure with us. We value your trust and ensure strict confidentiality.


Customized Research

Need tailored insights? Our analysts provide custom reports built on authentic data and aligned with your specific business goals.

FAQs

Yes, we are providing all research support to get resolve all queries and concerns regarding the report. For all our clients.
Yes, we are providing complete customization in every report to fulfill your business needs.
Yes, we are providing regional and countries level analysis in the report, please mention the countries you are looking.
Yes, we are providing a discount for individuals and startups.
We offer access to more than one million market research reports. If the specific topic you need is not listed on our website, simply email us your requirements at sales@chemreports.com. Our research team will review your request and provide a customized report or the most relevant available study. We?re always happy to assist you with tailored solutions.